Streetbeat News

Stock Prices

NFLX

OND

SOCL

SPOT

Keybanc analyst Justin Patterson maintained Spotify Technology SA (NYSE:SPOT) with an Overweight rating and raised the price target from $300 to $350, anticipating a surge in subscriber base and revenue per user. Patterson expects Spotify's 2024 revenue to be €15.4 billion and 2025 revenue to be €18.0 billion, with a slight increase in ARPU growth. He introduced a 2026 revenue forecast of €20.6 billion with an operating profit of €2.2 billion. The price target increase reflects higher revenue and profitability forecasts, with comparisons made to Netflix Inc's (NASDAQ:NFLX) EV/S multiple expansion. Spotify's stock has gained 130% in the last 12 months, and investors can also gain exposure through Global X Social Media ETF (NASDAQ:SOCL) and ProShares On-Demand ETF (NYSE:OND).

Portfolio Pulse from Anusuya Lahiri

April 12, 2024 | 5:32 pm

DHR

Deep-pocketed investors are showing a bearish sentiment towards Danaher (NYSE:DHR), with a significant move in options trading. Benzinga's tracking revealed 9 extraordinary options activities, with a majority being puts. The trading focuses on a price band between $230.0 and $247.5. Despite this, an analyst from Barclays maintains an Equal-Weight rating on DHR, with a target price of $260. The company's stock is currently down by -0.87%, with an earnings announcement expected in 11 days.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 5:32 pm

VZ

Recent analysis of Verizon Communications (NYSE:VZ) options activity reveals a split sentiment among big-money investors, with an equal number of bullish and bearish trades. The activity, involving both puts and calls, suggests expectations for VZ's stock price to fluctuate between $33.0 and $40.5. Despite this, the stock's current performance is slightly down, with neutral RSI indicators and upcoming earnings expected in 10 days. Market experts have varying opinions on VZ, with target prices ranging from $39 to $48.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 5:31 pm

SLGWF

SLANG Worldwide Inc. (OTCQB:SLGWF) reported a 56% YoY decrease in Q4 total comprehensive loss and a 37% decrease in Q4 revenue. FY 2023 saw a 7% revenue decrease but a 34% decrease in total comprehensive loss. The company highlighted a strategic focus on profitable growth, resulting in higher margins and lower operating expenses. SLANG's shares dropped 5.8824% to $0.028 per share following the announcement.

Portfolio Pulse from Jelena Martinovic

April 12, 2024 | 5:31 pm

MPWR

Over the past 15 years, Monolithic Power Systems (NASDAQ:MPWR) has delivered an average annual return of 27.8%, outperforming the market by 14.96% annually. A $100 investment in MPWR 15 years ago would be worth $3,955.91 today. The company's current market capitalization stands at $32.22 billion.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 5:30 pm

MSTR

Over the past 10 years, MicroStrategy (NASDAQ:MSTR) has produced an average annual return of 30.23%, outperforming the market by 19.63%. A $100 investment in MSTR a decade ago would now be worth $1,426.30, with the company currently valued at a market capitalization of $24.86 billion.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 5:30 pm

BLK

BlackRock, Inc. (NYSE:BLK) reported Q1 revenue growth of 11% year over year to $4.728 billion, beating consensus but saw shares trading lower due to concerns over fee rate dynamics. Management fees missed consensus by 1%, with equity fee rates and Alts fee rate declining. iShares drove $55 billion of flows, and despite mixed results, future growth is anticipated with significant mandates in wealth, institutional, and Aladdin sectors.

Portfolio Pulse from Nabaparna Bhattacharya

April 12, 2024 | 5:27 pm

CTLT

LLY

NVO

BMO Capital Markets initiated coverage on Novo Nordisk A/S (NVO) with an Outperform rating, highlighting its dominance in the obesity and diabetes drug market. The analysis points to Novo Nordisk and Eli Lilly (LLY) as leading players in this sector, with Novo's strong pipeline, including CagriSema and INV-202, expected to drive growth. The market, projected to reach over $130 billion, sees Novo and Lilly benefiting from manufacturing capabilities, with Catalent Inc (CTLT) also mentioned as a bolster to Novo's position. Trials for CagriSema and semaglutide are anticipated to push shares higher.

Portfolio Pulse from Vandana Singh

April 12, 2024 | 5:22 pm

SMCI

Super Micro Computer shares are trading lower due to a downturn in the broader tech stock market.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 5:20 pm

F

Ford shares are trading lower following the National Highway Traffic Safety Administration's (NHTSA) initiation of a recall query for 42,652 Ford SUVs due to potential fuel leak risks. The decline in Ford's stock price is also attributed to overall market weakness, driven by uncertainty regarding interest rate cuts.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 5:17 pm